CeriBell (NASDAQ:CBLL) Sees Large Volume Increase – Here’s What Happened

Posted by on Aug 11th, 2026

CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) shares saw unusually-strong trading volume on Tuesday . 690,708 shares were traded during mid-day trading, an increase of 109% from the previous session’s volume of 330,413 shares.The stock last traded at $20.7650 and had previously closed at $19.30.

Trending Headlines about CeriBell

Here are the key news stories impacting CeriBell this week:

  • Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $28 price target, implying roughly 33% potential upside from the referenced share price. The endorsement suggests the firm expects further appreciation based on CeriBell’s growth prospects. Benzinga
  • Positive Sentiment: CeriBell received FDA 510(k) clearance for two AI enhancements to its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. The tools are designed to help neurologists identify abnormal EEG patterns, reduce signal interference and interpret critical-care recordings more efficiently. The clearance could improve the clinical value of CeriBell’s platform and support hospital adoption. FDA clearance announcement
  • Positive Sentiment: Second-quarter revenue was $28.1 million, exceeding the $27.28 million analyst consensus. Management also issued fiscal 2026 revenue guidance of $114 million to $117 million, with the low end matching consensus expectations. CeriBell second-quarter results
  • Neutral Sentiment: Trading volume was substantially above the stock’s recent average, indicating heightened investor interest following the FDA announcement and earnings release.
  • Negative Sentiment: CeriBell reported a second-quarter loss of $0.51 per share, wider than the $0.45–$0.47 consensus loss and worse than the $0.38 loss recorded a year earlier. The company continues to report negative profitability metrics, including a negative net margin and return on equity. CeriBell Q2 earnings report
  • Negative Sentiment: Recent reported insider activity showed sales without purchases, which may create an overhang for sentiment, though such transactions do not necessarily indicate a change in the company’s outlook.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CBLL. Canaccord Genuity Group raised their price objective on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Finally, BTIG Research reissued a “buy” rating and set a $28.00 price target on shares of CeriBell in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.00.

Read Our Latest Report on CeriBell

CeriBell Price Performance

The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. The company has a 50 day simple moving average of $18.55 and a 200-day simple moving average of $19.08. The stock has a market cap of $822.79 million, a price-to-earnings ratio of -13.31 and a beta of 0.81.

CeriBell (NASDAQ:CBLL – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. As a group, research analysts anticipate that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

Insider Activity

In other news, CEO Xingjuan Chao sold 39,000 shares of CeriBell stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $19.90, for a total value of $776,100.00. Following the completion of the transaction, the chief executive officer directly owned 802,317 shares of the company’s stock, valued at approximately $15,966,108.30. The trade was a 4.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director William W. Burke sold 2,207 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $19.84, for a total transaction of $43,786.88. Following the sale, the director directly owned 23,022 shares of the company’s stock, valued at approximately $456,756.48. This represents a 8.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 300,685 shares of company stock valued at $5,935,326 over the last quarter. 17.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On CeriBell

Several institutional investors have recently made changes to their positions in CBLL. BlackRock Inc. acquired a new stake in shares of CeriBell during the 2nd quarter worth approximately $37,657,000. Bank of New York Mellon Corp boosted its position in CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after purchasing an additional 1,162,200 shares during the period. KCM Capital Inc bought a new position in CeriBell during the 4th quarter worth $21,930,000. TimesSquare Capital Management LLC acquired a new stake in CeriBell in the second quarter worth $15,182,000. Finally, Royce & Associates LP acquired a new stake in CeriBell in the fourth quarter worth $11,695,000.

CeriBell Company Profile

(Get Free Report)

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

Featured Stories

Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.